As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at outpatient & specialty care stocks, starting with LifeStance Health Group (NASDAQ: LFST).
The outpatient and specialty care industry delivers targeted medical services in non-hospital settings that are often cost-effective compared to inpatient alternatives. This means that they are more desired as rising healthcare costs and ways to combat them become more and more top-of-mind. Outpatient and specialty care providers boast revenue streams that are stable due to the recurring nature of treatment for chronic conditions and long-term patient relationships. However, their reliance on government reimbursement programs like Medicare means stroke-of-the-pen risk. Additionally, scaling a network of facilities can be capital-intensive with uneven return profiles amid competition from integrated healthcare systems. Looking ahead, the industry is positioned to grow as demand for outpatient services expands, driven by aging populations, a rising prevalence of chronic diseases, and a shift toward value-based care models. Tailwinds include advancements in medical technology that support more complex procedures in outpatient settings and the increasing focus on preventive care, which can be aided by data and AI. However, headwinds such as reimbursement rate cuts, labor shortages, and the financial strain of digitization may temper growth.
The 7 outpatient & specialty care stocks we track reported a mixed Q1. As a group, revenues beat analysts’ consensus estimates by 0.7% while next quarter’s revenue guidance was 0.8% below.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 9.3% since the latest earnings results.
LifeStance Health Group (NASDAQ: LFST)
With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ: LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.
LifeStance Health Group reported revenues of $333 million, up 10.8% year on year. This print was in line with analysts’ expectations, but overall, it was a mixed quarter for the company with an impressive beat of analysts’ EPS estimates but EBITDA guidance for next quarter missing analysts’ expectations significantly.
“We delivered a solid quarter to kick off 2025, thanks to the commitment and dedication of our employees, including over 7,500 clinicians,” said Dave Bourdon, CEO of LifeStance.
Unsurprisingly, the stock is down 13.4% since reporting and currently trades at $5.67.
Read our full report on LifeStance Health Group here, it’s free.
Best Q1: U.S. Physical Therapy (NYSE: USPH)
With a nationwide footprint spanning 671 clinics across 42 states, U.S. Physical Therapy (NYSE: USPH) operates a network of outpatient physical therapy clinics and provides industrial injury prevention services to employers across the United States.
U.S. Physical Therapy reported revenues of $183.8 million, up 18.1% year on year, outperforming analysts’ expectations by 4.4%. The business had an exceptional quarter with an impressive beat of analysts’ sales volume estimates and a decent beat of analysts’ EPS estimates.
U.S. Physical Therapy scored the biggest analyst estimates beat and fastest revenue growth among its peers. The market seems content with the results as the stock is up 4.3% since reporting. It currently trades at $73.89.
Is now the time to buy U.S. Physical Therapy? Access our full analysis of the earnings results here, it’s free.
Weakest Q1: Select Medical (NYSE: SEM)
With a nationwide network spanning 46 states and over 2,700 healthcare facilities, Select Medical (NYSE: SEM) operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers across the United States.
Select Medical reported revenues of $1.35 billion, up 2.4% year on year, falling short of analysts’ expectations by 2.6%. It was a softer quarter as it posted a significant miss of analysts’ EPS estimates and full-year revenue guidance missing analysts’ expectations.
Select Medical delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 22.5% since the results and currently trades at $14.13.
Read our full analysis of Select Medical’s results here.
DaVita (NYSE: DVA)
With over 2,600 dialysis centers across the United States and a presence in 13 countries, DaVita (NYSE: DVA) operates a network of dialysis centers providing treatment and care for patients with chronic kidney disease and end-stage kidney disease.
DaVita reported revenues of $3.22 billion, up 5% year on year. This number topped analysts’ expectations by 0.5%. Taking a step back, it was a slower quarter as it recorded a significant miss of analysts’ full-year EPS guidance estimates and a slight miss of analysts’ sales volume estimates.
The stock is down 4.1% since reporting and currently trades at $138.19.
Read our full, actionable report on DaVita here, it’s free.
Surgery Partners (NASDAQ: SGRY)
With more than 180 locations across 33 states serving as alternatives to traditional hospital settings, Surgery Partners (NASDAQ: SGRY) operates a national network of outpatient surgical facilities including ambulatory surgery centers and short-stay surgical hospitals.
Surgery Partners reported revenues of $776 million, up 8.2% year on year. This print met analysts’ expectations. However, it was a slower quarter as it produced a significant miss of analysts’ EPS estimates.
The stock is up 3% since reporting and currently trades at $22.80.
Read our full, actionable report on Surgery Partners here, it’s free.
Market Update
The Fed’s interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump’s presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025.
Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
